The U.S. Food and Drug Administration (FDA) approved a generic version of Liraglutide on January 14, 2026. This approval, granted under Abbreviated New Drug Application (ANDA) 217590, was for a product sponsored by ORBICULAR.
Background
Liraglutide is the active pharmaceutical ingredient in several established brand-name medications, including Victoza and Saxenda. The approval of a generic version means that the FDA has determined it is bioequivalent to its reference listed drug, ensuring comparable quality, safety, and efficacy.
What this means
The FDA's approval of a generic Liraglutide product from ORBICULAR is expected to increase patient access to this important medication. Generic drugs typically offer a more affordable treatment option, potentially reducing healthcare costs for individuals requiring Liraglutide for its approved indications.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) on January 14, 2026, as detailed in the agency's drug approval database on accessdata.fda.gov.